WO2017208088A3 - Compositions et méthodes pour le traitement de la maladie de parkinson - Google Patents
Compositions et méthodes pour le traitement de la maladie de parkinson Download PDFInfo
- Publication number
- WO2017208088A3 WO2017208088A3 PCT/IB2017/052235 IB2017052235W WO2017208088A3 WO 2017208088 A3 WO2017208088 A3 WO 2017208088A3 IB 2017052235 W IB2017052235 W IB 2017052235W WO 2017208088 A3 WO2017208088 A3 WO 2017208088A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- disease
- parkinson
- compositions
- treatment
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 206010070538 Gestational hypertension Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000011461 pre-eclampsia Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000006188 syrup Substances 0.000 abstract 1
- 235000020357 syrup Nutrition 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/30—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/49—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Cette invention concerne des composés de formule (I), formule (II) et formule (III) ou leurs sels pharmaceutiquement acceptables, ainsi que leurs polymorphes, solvates, énantiomères, stéréoisomères et hydrates. Les compositions pharmaceutiques comprenant une quantité efficace de composés de formule I, formule II et formule III, et les méthodes de traitement ou de prévention de la maladie de Parkinson selon l'invention peuvent être formulées pour une administration par voie orale, buccale, rectale, topique, transdermique, transmuqueuse, intraveineuse, parentérale, en sirop ou par injection. Ces compositions peuvent être utilisées pour le traitement ou la prise en charge de la maladie de Parkinson, de la sclérodermie, du syndrome des jambes sans repos, de l'hypertension et de l'hypertension gestationnelle.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641019113 | 2016-06-02 | ||
| IN201641019113 | 2016-06-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2017208088A2 WO2017208088A2 (fr) | 2017-12-07 |
| WO2017208088A3 true WO2017208088A3 (fr) | 2018-01-11 |
Family
ID=60479295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2017/052235 WO2017208088A2 (fr) | 2016-06-02 | 2017-04-19 | Compositions et méthodes pour le traitement de la maladie de parkinson |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2017208088A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2996260A1 (fr) * | 2015-09-02 | 2017-03-09 | Cellix Bio Private Limited | Compositions et methodes pour le traitement de la maladie de parkinson |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005041966A1 (fr) * | 2003-10-24 | 2005-05-12 | Nastech Pharmaceutical Company Inc. | Traitement de la maladie de parkinson par l'apomorphine en combinaison avec un promedicament apomorphinique |
| WO2013017974A1 (fr) * | 2011-07-30 | 2013-02-07 | Mahesh Kandula | Compositions et méthodes pour le traitement de troubles neuromusculaires et de maladies neurodégénératives |
-
2017
- 2017-04-19 WO PCT/IB2017/052235 patent/WO2017208088A2/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005041966A1 (fr) * | 2003-10-24 | 2005-05-12 | Nastech Pharmaceutical Company Inc. | Traitement de la maladie de parkinson par l'apomorphine en combinaison avec un promedicament apomorphinique |
| WO2013017974A1 (fr) * | 2011-07-30 | 2013-02-07 | Mahesh Kandula | Compositions et méthodes pour le traitement de troubles neuromusculaires et de maladies neurodégénératives |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017208088A2 (fr) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| TN2019000170A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| MX379545B (es) | Composiciones y metodos para el tratamiento del dolor cronico. | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| WO2013175377A3 (fr) | Compositions et méthodes pour le traitement de la mucosite | |
| WO2013175376A3 (fr) | Compositions et méthodes de traitement de la douleur locale | |
| MX386467B (es) | Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal) | |
| WO2014174425A3 (fr) | Compositions et méthodes de traitement de l'orthostasie et de maladies neurologiques | |
| MX2022005523A (es) | Composiciones y metodos para el tratamiento de infecciones fungicas. | |
| WO2020075023A3 (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| WO2016046680A3 (fr) | Compositions et procédés de traitement de maladies métaboliques hépatiques | |
| WO2014091384A3 (fr) | Compositions et méthodes pour le traitement de la mucosite | |
| WO2014068463A3 (fr) | Compositions et procédés de traitement d'une inflammation et de troubles métaboliques | |
| WO2014087307A3 (fr) | Compositions et procédés pour le traitement du syndrome métabolique et du diabète | |
| WO2013175359A3 (fr) | Compositions et méthodes pour le traitement de la sclérose en plaques | |
| BR112018076257A2 (pt) | compostos e composições farmacêuticas | |
| WO2014087323A3 (fr) | Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques | |
| WO2014006529A3 (fr) | Compositions et méthodes de traitement de la douleur modérée à aiguë | |
| WO2017208088A3 (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| MX383090B (es) | Composiciones y métodos para el tratamiento de enfermedades infecciosas orales. | |
| WO2014106804A3 (fr) | Compositions et procédés de traitement du syndrome métabolique et du diabète | |
| WO2014195850A3 (fr) | Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques | |
| WO2013167989A3 (fr) | Compositions et méthodes de traitement de troubles neurologiques | |
| WO2014097137A3 (fr) | Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques | |
| MX386208B (es) | Composiciones y métodos para el tratamiento de pólipos gastrointestinales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17805953 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17805953 Country of ref document: EP Kind code of ref document: A2 |